TY - JOUR
T1 - Treatment of mantle cell lymphoma
T2 - Current approach and future directions
AU - Brody, Joshua
AU - Advani, Ranjana
PY - 2006/6
Y1 - 2006/6
N2 - Although mantle cell lymphoma has been described as "moderately aggressive" it has become clear that it carries a worse long-term prognosis than other subtypes of non-Hodgkin's lymphoma. In recent years, this has prompted numerous clinical trials of novel and more aggressive therapies in hopes of impacting these poor outcomes. These include more intensive combination chemotherapy regimens, monoclonal antibody therapy in conjunction with other treatments or conjugated to radioactive isotopes, high-dose chemotherapy followed by autologous or allogeneic stem cell transplantation, and newer targeted therapies based on increasing understanding of the molecular pathways of this malignancy.
AB - Although mantle cell lymphoma has been described as "moderately aggressive" it has become clear that it carries a worse long-term prognosis than other subtypes of non-Hodgkin's lymphoma. In recent years, this has prompted numerous clinical trials of novel and more aggressive therapies in hopes of impacting these poor outcomes. These include more intensive combination chemotherapy regimens, monoclonal antibody therapy in conjunction with other treatments or conjugated to radioactive isotopes, high-dose chemotherapy followed by autologous or allogeneic stem cell transplantation, and newer targeted therapies based on increasing understanding of the molecular pathways of this malignancy.
KW - Clinical trials
KW - Mantle cell lymphoma
KW - Non-Hodgkin's lymphoma
UR - http://www.scopus.com/inward/record.url?scp=33748350890&partnerID=8YFLogxK
U2 - 10.1016/j.critrevonc.2005.10.001
DO - 10.1016/j.critrevonc.2005.10.001
M3 - Review article
C2 - 16751087
AN - SCOPUS:33748350890
SN - 1040-8428
VL - 58
SP - 257
EP - 265
JO - Critical Reviews in Oncology/Hematology
JF - Critical Reviews in Oncology/Hematology
IS - 3
ER -